AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06777654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT)
Description: The innovative mirror therapy (MT) program will be conducted with computerized mirror visual feedback and the conventional mirror box therapy. The unilateral MT group will practice on the unilateral module, while the bilateral MT group will practice based on the bilateral module. In the unilateral module, the affected hand will be static on the knee. In contrast, during bilateral MT, participants will be asked to do the same movements using the unaffected and affected arms as symmetrically as possible.
Study NCT06777654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dose-matched control intervention
Description: Participants in the control group will receive therapist-mediated rehabilitation per session.
Study NCT06164093 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RNA sequencing is performed on the remaining LPCs
Description: RNA sequencing is performed on the remaining LPCs previously transplanted back into the patients. And the results are analysed combined with the data from the previous clinical trial. (Please note that patients will not receive cell transplantation again as they have already received the treatment in the previous trial \[NCT03655808\])
Study NCT06164093 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immunofluorescence staining is performed in the surgically resected lung tissue sections
Description: The aim of this intervention is to detect Krt5 protein expression by staining the surgically resected lung tissue sections. This is done to confirm the presence of a small number of LPCs in the lung tissue of patients with bronchiectasis and to investigate their distribution.
Study NCT05168046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Description: program of weekly mindfulness based stress reduction intervention during 2 months and practice during 3 months
Study NCT05948553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention A Fluoxetine Hydrochloride (HCl)
Description: Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
Study NCT05948553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intervention A Placebo
Description: A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
Study NCT05551754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Beverage
Description: Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%
Study NCT05950945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
Study NCT04202406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will receive placebo (starch) 1hour before treatment.
Study NCT05420311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedDiet Arm
Description: A balanced hypocaloric diet in macronutrients (MedDiet)
Study NCT05420311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KetoDiet Arm
Description: A very low carbohydrate diet (KetoDiet).
Study NCT05420311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IF Arm
Description: An intermittent fasting (IF) approach
Study NCT05282030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolebrutinib
Description: Pharmaceutical form: Film-coated tablets Route of administration: oral
Study NCT05137197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Predictix Genetics Antidepressant
Description: Predictix Genetics Antidepressant (PGA) is a software tool that is intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with MDD.
Study NCT06483477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard skin care
Description: From the start of radiotherapy, standard skin care has to be performed by the patient. This may vary at the participating centers. At the site in Lübeck, it includes fatty cream with 2-10% urea (fatty cream alone, if patients do not tolerate urea) and, in case of pruritus, addition of mometasone furoate cream. In case of grade ≥2 moist desquamation or grade ≥3 radiation dermatitis, each day antiseptic agents will be administered for wound cleansing followed by administration of silicon or calcium alginate bandage. This treatment will be continued until moist desquamation radiation disappears and radiation dermatitis improves to grade 2. Fatty cream with 2-10% urea is applied to the irradiated skin four times daily. Mometasone furoate cream: In addition to the fatty cream with 2-10% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.
Study NCT06483477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard skin care
Description: From the start of radiotherapy, standard skin care has to be performed by the patient. This may vary at the participating centers. At the site in Lübeck, it includes fatty cream with 2-10% urea (fatty cream alone, if patients do not tolerate urea) and, in case of pruritus, addition of mometasone furoate cream. In case of grade ≥2 moist desquamation or grade ≥3 radiation dermatitis, each day antiseptic agents will be administered for wound cleansing followed by administration of silicon or calcium alginate bandage. This treatment will be continued until moist desquamation radiation disappears and radiation dermatitis improves to grade 2. Fatty cream with 2-10% urea is applied to the irradiated skin four times daily. Mometasone furoate cream: In addition to the fatty cream with 2-10% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.
Study NCT06483477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reminder App
Description: In addition to standard skin care, patients are supported by a Reminder App. The purpose of the app is to remind the patients in an intuitive, unobtrusive and supportive way to perform skin care. By default, patients are reminded four times a day, but they will also be able to define a notification schedule that best suits their personal needs. The patients may postpone each required care procedure for up to 2 hours. With each procedure, the patients are guided through the skin care with simple and self-explanatory illustrations. To increase the patients' motivation, they will additionally earn points for regular and punctual performed care procedures. The patients receive a hand-out including instructions how to properly perform skin care, but they can also find an information page within the application that includes similar instructions.
Study NCT06116526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab - Discontinuation
Description: Drug injections are discontinued.
Study NCT06116526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab - Dose Reduction
Description: The drug is given as a subcutaneous injection.
Study NCT06116526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab - Standard Dose
Description: The drug is given as a subcutaneous injection.
Study NCT04408638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.
Study NCT05697705 — intervention group
Intervention type: OTHER
Intervention: ChAdOx1 nCOV-19 vaccine (Vaxzeria)
Description: Used as 2nd booster, 1st booster, or primary series
Study NCT05697705 — intervention group
Intervention type: OTHER
Intervention: BNT162b2 (Pfizer)
Description: Used as 2nd booster, 1st booster, or primary series.
Study NCT05697705 — intervention group
Intervention type: OTHER
Intervention: Ad26.COV2.S (Janssen)
Description: Used as 2nd booster, 1st booster, or primary series.
Study NCT05397821 — intervention group
Intervention type: PROCEDURE
Intervention: UNC technique
Description: In general, UNC techniques can be divided in being either intravesical or extravesical and refluxing or non-refluxing
Study NCT05697705 — intervention group
Intervention type: OTHER
Intervention: CoronaVac (Sinovac)
Description: Used as 2nd booster, 1st booster, or primary series.
Study NCT05609929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration of omeprazole Single administration of AB-106
Description: Take AB-106 capsule 400 mg orally on an empty stomach in the morning of the first day of the first cycle Take omeprazole magnesium enteric coated tablets 40mg once a day, 30 minutes before breakfast on days 1-4 of the second cycle. On the morning of the fifth day of the second cycle, the subjects will take omeprazole magnesium enteric coated tablets 40 mg, and AB-106 capsules 400 mg after an interval of 1 hour
Study NCT06062875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
Study NCT04408638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive IV glofitamab for up to 12 cycles.
Study NCT04408638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxumab
Description: Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.
Study NCT04408638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).
Study NCT04408638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
Study NCT06146452 — intervention group
Intervention type: OTHER
Intervention: Not
Description: Not
Study NCT05593575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127+SPH3127matching placebo+valsartan matching placebo
Description: 1 tablet of SPH3127 (50 mg) ，3 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
Study NCT05593575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127+SPH3127matching placebo+valsartan matching placebo
Description: 2 tablet of SPH3127 (50 mg) ，2 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
Study NCT05593575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127+valsartan matching placebo
Description: 4 tablet of SPH3127 (50 mg) ， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
Study NCT05593575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 matching placebo+valsartan
Description: 4 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan, orally, once daily for 12 consecutive weeks
Study NCT04859023 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva sample combined to an anterior nare self-swabbing (Self-samples)
Description: Tested by antigenic test.
Study NCT04859023 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva sample (Self-sample)
Description: Tested by RT-PCR.
Study NCT06053424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Solution
Study NCT06053424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]AZ14132516
Description: Radioligand
Study NCT06356584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Immunotherapy
Study NCT06230380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with autofluorescence
Description: In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize PTGs during surgery. The surgical field will be visualized with AF as a minimum of two times during surgery on each side of the neck: First upon exposing the undersurface of the thyroid gland, and secondly before removal of a pathological PTG. Also, removed PTGs will be examined ex vivo to document AF pattern.
Study NCT05821283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise program consisting of supervised exercise and physical activity
Description: The Physical Activity Group (PAG) included in an exercise program consisting of supervised exercise and physical activity (30 minutes of moderate-intensity walking). Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions.The physical activity program was applied as moderate intensity (maximum heart rate 50-70%) walking exercise. The patients were recommended to walk for 30 minutes, 3 days a week (total of 90 minutes) for the first 3 weeks, and 30 minutes 5 days a week (total of 150 minutes) for the 2nd 3 weeks
Study NCT05821283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercise program consisting of only supervised exercises.
Description: The Control Group (CG) included in the program consisting of only supervised exercises. Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions
Study NCT05681520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEEPS
Description: Working with a peer specialist for six 30-minute sessions to enhance engagement in pain management approaches/treatments
Study NCT05456685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine
Description: Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called FRα. It is being developed for the treatment of participants with recurrent platinum-sensitive, high grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with FRα expression. FRα positivity will be defined by the Ventana FOLR1 Assay.
Study NCT05456685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is considered to be the treatment agent of choice in relapsed PSOC.
Study NCT06004973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STAR Particles
Description: A 1.5-gram dose of STAR particles (10% concentration in aloe vera ointment) will be applied to the eight application sites (forearm and hand) and 100 mg of aloe vera will be applied to the control site on one of the forearms. Two rubbing cycles (20 and 30 cycles at 1 cycle/second) and three pressures (40, 60, and 80 kPa) will be evaluated.
Study NCT04408638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
Study NCT04859023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey of SARS-COV-19 knowledge
Description: collection of : socio-professional characteristics, questions on health literacy on the transmission of the virus and barrier gestures, adherence to barrier gestures, isolation modalities in case of positivity, motivations for participating in this screening campaign.
Study NCT04859023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey of acceptability of the different self-samples.
Description: collection of : assessment and acceptability of the tolerance of self-samples.
Study NCT04778631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Application of warm compresses, soaked in hot tap water (between 38° and 44 °C), to the perineum, at each contraction or pushing effort from the start of perineum distension until birth.
Study NCT04778631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Application of a perineal instant col pack to the perineum, after placental delivery or perineum suturing, for at least 20 minutes.
Study NCT06657118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided arthrocentesis of tempromandibular joint
Description: * Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* Transducer is placed over TMJ, parallel to the long axis of mandibular ramus. • Transducer is tilted until the optimal visualization is obtained.~* Disc is visualized as a thin homogenous, hypo-to-iso-echoic band lying adjacent to the inferior relation. The bony landmarks of the mandibular condyle and the articular eminence are visualized as hyperdense lines.~* Superior joint space located between the disc and articular eminence is the targeted point of the needle.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours
Study NCT06657118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional anatomically guided arthrocentesis of tempromandibular joint
Description: * Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* A line will be drawn from tragus of the ear to the outer canthus of the eye with ink.~* Double needled canula is inserted into superior compartment of the joint space 2mm below and 10 mm ahead of mid-tragal end of Holmund Hellsing's line.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours
Study NCT06662084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: phenotype
Description: Eligible patients will receive orally the cocktail probe drugs ( via a naso-gastric tube at D3 after tMCS implantation or after the beginning of the cardiogenic shock for the control group) and via an oral administration at 14 days after tMCS explantation (or cardiogenic shock termination for the control group defined as: no need to use inortropic or vasopressive agent and absence of organ insufficiency). The phenotyping probe drugs of the Geneva Cocktail will be given as: one capsule containing the remaining probe 'cocktail' drugs. According to clinical experience in our intensive care unit department, inflammation related to tMCS peaks at D3 after tMCS implantation.~Blood samples will be collected from the central venous line 2 hours after drug administration for CYP phenotyping and genotyping. Inflammatory markers blood levels (Il-6, TNF-α, Il-1β, IFN-γ) will be measured at tMCS implantation or shock initiation and at the same time than CYP phenotyping.
Study NCT06661148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-003
Description: Intravenous (IV) infusion.
Study NCT06215560 — intervention group
Intervention type: OTHER
Intervention: PDMP Check CDS
Description: Clinical decision support in the form of a EHR-integrated, provider facing alert suggesting providers consult the patient PDMP in line with State legislation.
Study NCT06075745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMV-MVA Triplex
Description: The dosage used will be 5.0 x 10\^8 pfu, administered under sterile conditions intramuscularly. The CMV-MVA Triplex vaccine lots range in titre from 5.0 to 9.0 x 10\^8 pfu/mL in a supplied volume of 1.0 mL
Study NCT06659380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metronidazole + Floragyn® probiotic tablets (Lapi, Indonesia)
Description: Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~One tablet Floragyn contains Lactobacillus rhamnosus and lactobacillus reuteri, bacteria that are normal flora (good bacteria) of the vagina.
Study NCT06659380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole + Cal95
Description: Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~Cal 95 is a supplement containing multivitamins and minerals including: Calcium, Zinc, Boron and Magnesium. This tablet is used to help meet calcium needs and maintain bone health in menopausal women.
Study NCT06659380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Floragyn® probiotic tablets (Lapi, Indonesia)
Description: Given to the control group to ensure the ability of probiotics to maintain a healthy vaginal ecosystem and not the opposite.
Study NCT06660628 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Large Segmentation Radiotherapy
Description: Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold
Study NCT06660628 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Large Segmentation Radiotherapy
Description: Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold
Study NCT06660628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIBH
Description: Deep Inspiration Breath Hold